Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TAVO412 |
| Synonyms | |
| Therapy Description |
TAVO412 is a trispecific antibody that targets MET, EGFR, and VEGF, potentially resulting in inhibition of tumor growth (Cancer Res (2023) 83 (5_Supplement): P2-24-05). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TAVO412 | TAVO 412|TAVO-412 | EGFR Antibody 72 MET Antibody 37 VEGF Antibody 15 | TAVO412 is a trispecific antibody that targets MET, EGFR, and VEGF, potentially resulting in inhibition of tumor growth (Cancer Res (2023) 83 (5_Supplement): P2-24-05). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05548634 | Phase I | TAVO412 | A Study of TAVO412 in Patients With Cancer (TAVO412) | Active, not recruiting | USA | 0 |